Hollis-Eden related Press Releases
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONETM (HE3235) in Preclinical Models of Castration-Re
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONETM (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer September 29, 2008 SAN DIEGO--(BUSINESS... Read more...
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235
Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer SAN DIEGO -- Oct 4, 2007 - Hollis-Eden Pharmaceuticals the... Read more...
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium
Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals,... Read more...
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




